OM:MOB

Stock Analysis Report

Executive Summary

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally.


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Moberg Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MOB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.8%

MOB

0.7%

SE Pharmaceuticals

0.09%

SE Market


1 Year Return

-74.7%

MOB

9.2%

SE Pharmaceuticals

22.0%

SE Market

Return vs Industry: MOB underperformed the Swedish Pharmaceuticals industry which returned 9.2% over the past year.

Return vs Market: MOB underperformed the Swedish Market which returned 22% over the past year.


Shareholder returns

MOBIndustryMarket
7 Day3.8%0.7%0.09%
30 Day-15.8%5.6%4.7%
90 Day-58.4%16.0%11.1%
1 Year-74.7%-74.7%11.9%9.2%26.9%22.0%
3 Year-68.7%-68.7%32.5%20.4%40.1%18.9%
5 Year-62.6%-62.6%9.0%-6.6%46.5%15.4%

Price Volatility Vs. Market

How volatile is Moberg Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Moberg Pharma undervalued compared to its fair value and its price relative to the market?

18.6%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MOB (SEK17.3) is trading below our estimate of fair value (SEK21.27)

Significantly Below Fair Value: MOB is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: MOB is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: MOB is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MOB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MOB is good value based on its PB Ratio (0.3x) compared to the SE Pharmaceuticals industry average (4.3x).


Next Steps

Future Growth

How is Moberg Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-3.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: MOB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MOB's is expected to become profitable in the next 3 years.

Revenue vs Market: MOB's revenue (59.3% per year) is forecast to grow faster than the Swedish market (4.7% per year).

High Growth Revenue: MOB's revenue (59.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MOB's Return on Equity is forecast to be low in 3 years time (19.9%).


Next Steps

Past Performance

How has Moberg Pharma performed over the past 5 years?

-17.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MOB is currently unprofitable.

Growing Profit Margin: MOB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MOB is unprofitable, and losses have increased over the past 5 years at a rate of -17.9% per year.

Accelerating Growth: Unable to compare MOB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MOB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.1%).


Return on Equity

High ROE: MOB has a negative Return on Equity (-0.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Moberg Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: MOB's short term assets (SEK932.1M) exceed its short term liabilities (SEK56.9M).

Long Term Liabilities: MOB's short term assets (SEK932.1M) exceed its long term liabilities (SEK32.0M).


Debt to Equity History and Analysis

Debt Level: MOB's debt to equity ratio (2.1%) is considered satisfactory.

Reducing Debt: MOB's debt to equity ratio has reduced from 8.6% to 2.1% over the past 5 years.


Balance Sheet

Inventory Level: MOB has a low level of unsold assets or inventory.

Debt Coverage by Assets: MOB's debt is covered by short term assets (assets are 39.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOB has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: MOB has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is Moberg Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.6%markettop25%4.2%industryaverage2.8%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate MOB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate MOB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MOB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MOB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MOB's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Anna Ljung (39yo)

0.8yrs

Tenure

kr476,000

Compensation

Ms. Anna Ljung, M.Sc., BA has been Chief Executive Officer of Moberg Pharma AB (publ) since May 16, 2019. Ms. Ljung served as the Chief Financial Officer at Moberg Pharma AB (publ) (alternate name: Moberg  ...


CEO Compensation Analysis

Compensation vs Market: Anna's total compensation ($USD48.95K) is below average for companies of similar size in the Swedish market ($USD207.34K).

Compensation vs Earnings: Insufficient data to compare Anna's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Wolpert
Co-Founder & Executive Chairman0.8yrskr3.60mno data
Anna Ljung
Chief Executive Officer0.8yrskr476.00k0.075% SEK242.1k
Marie Moberg
Co-Founder13.9yrskr193.70kno data
Mark Beveridge
Vice President of Finance0.3yrsno data0.20% SEK658.1k
Gunilla Wengström
Senior Director of Sales & Marketing1.1yrsno datano data
Torbjörn Wärnheim
Deputy CEO0.8yrsno data0.036% SEK114.8k

0.9yrs

Average Tenure

45.5yo

Average Age

Experienced Management: MOB's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Peter Wolpert
Co-Founder & Executive Chairman0.8yrskr3.60mno data
Howard Maibach
Member of Scientific Advisory Board0yrsno datano data
Andrew Hochman
Independent Director0.9yrskr28.00kno data
Fredrik Granström
Independent Director0.8yrskr28.00kno data
Mattias Klintemar
Independent Director4.8yrskr108.00k0.037% SEK121.1k
Jan Faergemann
Member of Scientific Advisory Board0yrsno datano data
Lennart Emtestam
Member of Scientific Advisory Board0yrsno datano data
Johan Heilborn
Member of Scientific Advisory Board0yrsno datano data
Bernt Lindelöf
Member of Scientific Advisory Board0yrsno datano data

0.8yrs

Average Tenure

51yo

Average Age

Experienced Board: MOB's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MOB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Moberg Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Moberg Pharma AB (publ)
  • Ticker: MOB
  • Exchange: OM
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr322.970m
  • Shares outstanding: 18.67m
  • Website: https://www.mobergpharma.se

Number of Employees


Location

  • Moberg Pharma AB (publ)
  • Gustavslundsvägen 42
  • 5th Floor
  • Bromma
  • Stockholm County
  • 167 51
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MOBOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKMay 2011
MB8ADB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2011
MBGR.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2011

Biography

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products for skin diseases in Sweden, the United States, and internationally. It develops MOB-015, which is under Phase III clinical trial for the treatment of nail fungus treatment; and BUPI, a lozenge with bupivacaine intended for pain relief in association with inflammation and ulceration of the oral mucous membranes. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was founded in 2006 and is headquartered in Bromma, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/22 22:25
End of Day Share Price2020/02/21 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.